This article is more than 5 years old. Information may no longer be current.

AMO receives FDA approval for Healon D viscoelastic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA, Calif. — Advanced Medical Optics has received premarket approval from the U.S. Food and Drug Administration for its Healon D viscoelastic, the company announced in a press release.

Healon D is a low-weight, latex-free dispersive ophthalmic viscosurgical device that can be applied to the cornea to protect endothelial cells during cataract extraction, IOL implantation, corneal transplantation and glaucoma filtration surgery. In addition, Healon D's lower viscosity can provide good lubrication for IOL insertion systems, the release said.

AMO also plans to introduce two new dual combination packs, which will include Healon D and either Healon GV (1.4% sodium hyaluronate) or standard Healon (sodium hyaluronate), according to the release.

AMO plans to begin distributing Healon D and the new combination packs later this year.